These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34361688)

  • 1. Trans-(-)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?
    Rattanaburee T; Tanawattanasuntorn T; Thongpanchang T; Tipmanee V; Graidist P
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation.
    Rattanaburee T; Tipmanee V; Tedasen A; Thongpanchang T; Graidist P
    Biomed Pharmacother; 2020 Sep; 129():110361. PubMed ID: 32535390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-Kusunokinin and piperloguminine from Piper nigrum: An alternative option to treat breast cancer.
    Sriwiriyajan S; Sukpondma Y; Srisawat T; Madla S; Graidist P
    Biomed Pharmacother; 2017 Aug; 92():732-743. PubMed ID: 28586745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
    Tedasen A; Dokduang S; Sukpondma Y; Lailerd N; Madla S; Sriwiriyajan S; Rattanaburee T; Tipmanee V; Graidist P
    Eur J Pharmacol; 2020 Sep; 882():173311. PubMed ID: 32619673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Stereoselective Binding of
    Chompunud Na Ayudhya C; Graidist P; Tipmanee V
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
    Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer activity of synthetic (±)-kusunokinin and its derivative (±)-bursehernin on human cancer cell lines.
    Rattanaburee T; Thongpanchang T; Wongma K; Tedasen A; Sukpondma Y; Graidist P
    Biomed Pharmacother; 2019 Sep; 117():109115. PubMed ID: 31220743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
    Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
    Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer effects of Piper nigrum via inducing multiple molecular signaling in vivo and in vitro.
    Deng Y; Sriwiriyajan S; Tedasen A; Hiransai P; Graidist P
    J Ethnopharmacol; 2016 Jul; 188():87-95. PubMed ID: 27155135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
    Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
    Watson SS; Dane M; Chin K; Tatarova Z; Liu M; Liby T; Thompson W; Smith R; Nederlof M; Bucher E; Kilburn D; Whitman M; Sudar D; Mills GB; Heiser LM; Jonas O; Gray JW; Korkola JE
    Cell Syst; 2018 Mar; 6(3):329-342.e6. PubMed ID: 29550255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.